Chudi Ndubaku has been an Associate Director of Chemistry at Aduro Biotech since 2015. Prior to joining Aduro, he was a Senior Scientist in the Department of Discovery Chemistry at Genentech. He received a B.S. in Chemistry from University of California Berkeley and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology under the supervision of Prof. Tim Jamison. His research interests span the field of Medicinal Chemistry as it applies to the areas of oncology, ophthalmology, immunology and neurology. He contributed to the discovery of several clinical compounds, including taselisib – a PI3K alpha-mutant inhibitor currently in Phase III trials.